21.02.2020 • News

Merck KGaA to Sell Allergopharma to Dermapharm

Merck KGaA to Sell Allergopharma to Dermapharm
Merck KGaA to Sell Allergopharma to Dermapharm

As part of its new strategy to concentrate on innovative medicines for the unmet medical needs of patients with difficult-to-treat diseases, Germany’s Merck KGaA has decided to shed its allergy franchise. It has now agreed to sell subsidiary Allergopharma to compatriot Dermapharm Holding, based at Grünwald near Munich.

No price tag has been named for the transaction, which is expected to close by the end of the second quarter, subject to all customary conditions. The transfer includes the Allergopharma business in Europe and Asia, with a therapeutic and diagnostic product portfolio with sales of €88 million annually and a production site in Reinbek near Hamburg, Germany.

Allergopharma’s adrenaline autoinjector development project for the treatment of anaphylactic reactions is not part of the transaction and will remain with Merck.

The specialized company, which markets its treatments in 18 countries worldwide, is regarded a leader in allergen-specific immunotherapy of type 1 allergies such as hay fever or allergic asthma.

Merck said the transfer of Allergopharma to Dermapharm, a leading manufacturer of off-patent branded medicines for selected markets in Germany, will substantially strengthen its business.

Dermapharm is a leading manufacturer of off-patent branded medicines for selected markets in Germany, with its main production site at Brehna near Leipzig. The company has more than 900 marketing authorizations for around 250 active ingredients that are commercialized either as medicines, food supplements or supplemental balanced diets.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read